Table 3 Total and incremental results (bedaquiline plus BR versus BR) in the high burden countries analyzed

 Population^a, cases (n)

38

6,537

6,494

564

826

11

20,763

 Bedaquiline + BR

438.41

72,824.26

78,816.95

8,318.51

7,329.94

152.50

299,598.12

 BR only

554.29

90,479.07

96,530.04

10,475.26

9,792.45

177.64

384,990.40

 Bedaquiline + BR

11.54

11.14

12.14

14.75

8.87

13.86

14.43

 BR only

14.59

13.84

14.86

18.57

11.86

16.15

18.54

 Incremental change in DALYs (bedaquiline + BR vs. BR) (%, relative to bedaquiline)

-20.90

-19.51

-18.35

-20.59

-25.15

-14.16

-22.18

 Bedaquiline + BR

40.66

38.67

36.50

40.09

47.25

28.69

42.76

 BR only

26.29

24.83

23.55

25.88

31.16

17.85

27.97

 Incremental change in successful outcomes (bedaquiline + BR vs. BR) (%, relative to bedaquiline)

+54.67

+55.78

+55.02

+54.87

+51.62

+60.78

+52.87

 Bedaquiline + BR

2.16

349.72

28.20

31.88

52.90

0.50

1,274.00

 BR only

3.16

512.37

47.58

46.63

77.04

0.73

1,862.89

 Incremental change in acquired resistance (bedaquiline + BR vs. BR) (%, relative to bedaquiline)

-31.59

-31.75

-40.8

-31.62

-31.34

-32.22

-31.61